These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 23406550)

  • 1. Effects of aspirin on cancer initiation and progression.
    Choe KS; Liauw SL
    Expert Rev Anticancer Ther; 2013 Feb; 13(2):115-7. PubMed ID: 23406550
    [No Abstract]   [Full Text] [Related]  

  • 2. An introduction to aspirin, NSAids, and COX-2 inhibitors for the primary prevention of cardiovascular events and cancer and their potential preventive role in bladder carcinogenesis: part II.
    Moyad MA
    Semin Urol Oncol; 2001 Nov; 19(4):306-16. PubMed ID: 11769882
    [TBL] [Abstract][Full Text] [Related]  

  • 3. More evidence that aspirin lowers cancer risk.
    Sinha G
    J Natl Cancer Inst; 2015 Jan; 107(1):495. PubMed ID: 25564600
    [No Abstract]   [Full Text] [Related]  

  • 4. Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study.
    Gurbel PA; Bliden KP; DiChiara J; Newcomer J; Weng W; Neerchal NK; Gesheff T; Chaganti SK; Etherington A; Tantry US
    Circulation; 2007 Jun; 115(25):3156-64. PubMed ID: 17562955
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new cyclooxygenase-2 inhibitor, rofecoxib (VIOXX), did not alter the antiplatelet effects of low-dose aspirin in healthy volunteers.
    Greenberg HE; Gottesdiener K; Huntington M; Wong P; Larson P; Wildonger L; Gillen L; Dorval E; Waldman SA
    J Clin Pharmacol; 2000 Dec; 40(12 Pt 2):1509-15. PubMed ID: 11185674
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aspirin resistance and atherothrombotic disease.
    Maree AO; Jneid H; Fitzgerald DJ
    J Am Coll Cardiol; 2006 Aug; 48(4):846-7; author reply 847. PubMed ID: 16904562
    [No Abstract]   [Full Text] [Related]  

  • 7. Inflammatory pathogenesis of prostate cancer and celecoxib.
    Mathew P
    J Clin Oncol; 2010 Apr; 28(12):e197; author reply e198. PubMed ID: 20177014
    [No Abstract]   [Full Text] [Related]  

  • 8. Aspirin, the new targeted therapy in colorectal cancer.
    Fuchs CS
    Clin Adv Hematol Oncol; 2014 Mar; 12(3):186-9. PubMed ID: 24927268
    [No Abstract]   [Full Text] [Related]  

  • 9. The aspirin resistance controversy: clinical entity or platelet heterogeneity?
    Freedman JE
    Circulation; 2006 Jun; 113(25):2865-7. PubMed ID: 16801473
    [No Abstract]   [Full Text] [Related]  

  • 10. Colorectal cancer chemoprevention: ready for practice?
    Kraus S; Arber N
    Eur J Cancer; 2009 Sep; 45 Suppl 1():360-6. PubMed ID: 19775633
    [No Abstract]   [Full Text] [Related]  

  • 11. The multiple effects of aspirin in prostate cancer patients.
    Joshi SN; Murphy EA; Olaniyi P; Bryant RJ
    Cancer Treat Res Commun; 2021; 26():100267. PubMed ID: 33360326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistance.
    Frelinger AL; Furman MI; Linden MD; Li Y; Fox ML; Barnard MR; Michelson AD
    Circulation; 2006 Jun; 113(25):2888-96. PubMed ID: 16785341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Are we ready to recommend aspirin for cancer prevention?
    Chan AT; Cook NR
    Lancet; 2012 Apr; 379(9826):1569-71. PubMed ID: 22440945
    [No Abstract]   [Full Text] [Related]  

  • 14. Cyclooxygenase-2: a therapeutic target for prostate cancer.
    Pruthi RS; Wallen EM
    Clin Genitourin Cancer; 2005 Dec; 4(3):203-11. PubMed ID: 16425990
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aspirin and other cyclooxygenase inhibitors: new therapeutic insights.
    Wu KK
    Semin Vasc Med; 2003 May; 3(2):107-12. PubMed ID: 15199473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased platelet sensitivity among individuals with aspirin resistance - platelet aggregation to submaximal concentration of arachidonic acid predicts response to antiplatelet therapy.
    Guthikonda S; Mangalpally K; Vaduganathan M; Patel R; Delao T; Bergeron AL; Dong JF; Lev EI; Kleiman NS
    Thromb Haemost; 2008 Jul; 100(1):83-9. PubMed ID: 18612542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rational use of analgesic and antiinflammatory drugs.
    Crofford LJ
    N Engl J Med; 2001 Dec; 345(25):1844-6. PubMed ID: 11752364
    [No Abstract]   [Full Text] [Related]  

  • 18. Prevalence of aspirin resistance in stroke patients in Phramongkutklao Hospital.
    Nidhinandana S; Changchit S
    J Med Assoc Thai; 2010 Nov; 93 Suppl 6():S51-4. PubMed ID: 21280515
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin.
    Burnakis TG
    N Engl J Med; 2002 May; 346(20):1589-90; author reply 1589-90. PubMed ID: 12015403
    [No Abstract]   [Full Text] [Related]  

  • 20. Celecoxib does not affect the antiplatelet activity of aspirin in healthy volunteers.
    Wilner KD; Rushing M; Walden C; Adler R; Eskra J; Noveck R; Vargas R
    J Clin Pharmacol; 2002 Sep; 42(9):1027-30. PubMed ID: 12211219
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.